Please assess the completion status of the following clinical trial:

Trial Title: Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients willing to participate with confirmed diagnosis of COPD~* 40 years of age or older~* having a 10 pack year smoking history~* able to perform serial pulmonary function tests~* able to use both a DPI and Respimat device~Exclusion Criteria:~* Significant other disease~* clinically relevant abnormal hematology, chemistry, or urinalysis~* history of asthma~* diagnosis of thyrotoxicosis~* paroxysmal tachycardia related to beta agonists~* history of MI within 1 year, cardiac arrhythmia, hospitalization for heart failure within 1 year~* active tuberculosis, cystic fibrosis, clinically evident bronchiectasis~* significant alcohol or drug use~* pulmonary resection~* taking oral beta adrenergics~* taking unstable oral steroids~* daytime oxygen~* enrolled in rehabilitation program~* enrolled in another study or taking investigational products~* pregnant or nursing women, women of child bearing potential not willing to use two methods of birth control~* those who are not willing to comply with pulmonary medication washouts

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 1744 (Olodaterol) Low Dose (Type: EXPERIMENTAL): BI1744 Low Dose once daily
- BI 1744 (Olodaterol) Med Dose (Type: EXPERIMENTAL): BI 1744 Med Dose once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily
- Foradil (Type: ACTIVE_COMPARATOR): Foradil 12 mcg twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).